Back to News
Market Impact: 0.25
Clene Announces $4M Registered Direct Offering; Funding Expected Through Q1 2027
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Clene Inc. priced a $4 million registered direct equity offering of 1,219,513 shares at $3.28 per share. The financing provides capital for the clinical-stage ALS and neurodegenerative-disease developer but may dilute existing shareholders.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
CLNN-0.45
More News
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid
- Trip.com swings to Q2 loss after $763 million antitrust penalty
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Reliance Worldwide shares hit 1-year high on Brookfield’s $2.9 bln deal
- Why Dave & Buster's Stock Tumbled Today
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)
- AI for M&A Target Screening: From Universe to Deal File